Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olodanrigan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 known ✓ | P50052 | 19/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olodanrigan SCHEMBL8964136 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL244657 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL29394365 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3516607 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL8964206 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3514261 | 0.94 | AGTR2 (0.88) | AGTR2AGTR1 | |
| SCHEMBL8964101 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3519228 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3516610 | 0.94 | AGTR2 (0.88) | AGTR2AGTR1 | |
| SCHEMBL8964686 | 0.92 | AGTR2 (0.87) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987343-B2 | Compositions and methods for treating pulmonary diseases | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-04-27 | — | — | US | claimed |
| US-20190152918-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | RATIOPHARM GMBH (DE) | 2019-05-23 | — | — | US | claimed |
| EP-3475261-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | ratiopharm GmbH (DE) | 2019-05-01 | — | — | EP | claimed |
| US-20190070153-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASES | CASE WESTERN RESERVE UNIVERSITY | 2019-03-07 | — | — | US | claimed |
| WO-2018001997-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | RATIOPHARM GMBH (DE) | 2018-01-04 | — | — | WO | claimed |
| WO-2017062988-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-04-13 | — | — | WO | claimed |
| EP-3081557-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Novartis AG (CH) | 2016-10-19 | — | — | EP | claimed |
| EP-2595960-B1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2016-02-24 | — | — | EP | claimed |
| EP-2525795-B1 | METHODS AND COMPOSITIONS FOR IMPROVED NERVE CONDUCTION VELOCITY | SPINIFEX PHARM PTY LTD (AU) | 2015-10-21 | — | — | EP | claimed |
| US-9162985-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-10-20 | — | — | US | claimed |
| US-9095587-B2 | Methods and compositions for improved nerve conduction velocity | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-04 | — | — | US | claimed |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-16 | — | — | US | claimed |
| US-8927575-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-06 | — | — | US | claimed |
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-03-20 | — | — | US | claimed |
| US-8614227-B2 | Salt and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-12-24 | — | — | US | claimed |
| EP-2595960-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Spinifex Pharmaceuticals Pty Ltd (AU) | 2013-05-29 | — | — | EP | claimed |
| US-20130131103-A1 | Methods and Compositions For Improved Nerve Conduction Velocity | NOVARTIS AG (CH) | 2013-05-23 | — | — | US | claimed |
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD, (AU) | 2012-01-26 | — | — | US | claimed |
| WO-2012010843-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2012-01-26 | — | — | WO | claimed |
| WO-2024009283-A1 | AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230242522-A1 | SALT OF TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242522-A1 | SALT OF TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| EP-4177253-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-4096648-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | Gillies Mcindoe Research Institute (NZ) | 2022-12-07 | — | — | EP | disclosed |
| US-11384097-B2 | Tetrahydroisoquinoline derivative, preparation method therefor and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
| WO-2022001847-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 浙江海正药业股份有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-11198861-B2 | Engineered phenylalanine ammonia lyase polypeptides | CODEXIS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210277021-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-09-09 | — | — | US | disclosed |
| WO-2021154102-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | DAVIS PAUL FRANK (NZ) | 2021-08-05 | — | — | WO | disclosed |
| US-20210206724-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-06-01 | — | — | US | disclosed |
| EP-3019477-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-3819293-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2021-05-12 | — | — | EP | disclosed |
| US-10987343-B2 | Compositions and methods for treating pulmonary diseases | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2020228436-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2020-11-19 | — | — | WO | disclosed |
| US-20200206196-A1 | Antiviral Drugs | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-07-02 | — | — | US | disclosed |
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-02 | — | — | US | disclosed |
| WO-2020012266-A1 | BIOCATALYTIC SYNTHESIS OF OLODANRIGAN (EMA401) FROM 3-(2-(BENZYLOXY)-3-METHOXYPHENYL)PROPENOIC ACID WITH PHENYLALANINE AMMONIA LYASE | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012266-A1 | BIOCATALYTIC SYNTHESIS OF OLODANRIGAN (EMA401) FROM 3-(2-(BENZYLOXY)-3-METHOXYPHENYL)PROPENOIC ACID WITH PHENYLALANINE AMMONIA LYASE | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| US-20200017845-A1 | ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-01-16 | — | — | US | disclosed |
| WO-2019242599-A1 | TETRAHYDRO ISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2019-12-26 | — | — | WO | disclosed |
| US-10308628-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-20190152918-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | RATIOPHARM GMBH (DE) | 2019-05-23 | — | — | US | disclosed |
| US-20190152918-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | RATIOPHARM GMBH (DE) | 2019-05-23 | — | — | US | disclosed |
| US-20190152918-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | RATIOPHARM GMBH (DE) | 2019-05-23 | — | — | US | disclosed |
| EP-3475261-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | ratiopharm GmbH (DE) | 2019-05-01 | — | — | EP | disclosed |
| EP-3475261-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | ratiopharm GmbH (DE) | 2019-05-01 | — | — | EP | disclosed |
| EP-3475261-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | ratiopharm GmbH (DE) | 2019-05-01 | — | — | EP | disclosed |
| US-20190070153-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASES | CASE WESTERN RESERVE UNIVERSITY | 2019-03-07 | — | — | US | disclosed |
| WO-2018172950-A1 | ANHYDROUS CRYSTALLINE FORMS OF SODIUM (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINECARBOXYLATE | NOVARTIS AG (CH) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018172950-A1 | ANHYDROUS CRYSTALLINE FORMS OF SODIUM (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINECARBOXYLATE | NOVARTIS AG (CH) | 2018-09-27 | — | — | WO | disclosed |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180057477-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2018-03-01 | — | — | US | disclosed |
| EP-3268356-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| WO-2018001997-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | RATIOPHARM GMBH (DE) | 2018-01-04 | — | — | WO | disclosed |
| WO-2018001997-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | RATIOPHARM GMBH (DE) | 2018-01-04 | — | — | WO | disclosed |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-12-28 | — | — | US | disclosed |
| EP-3245198-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | Novartis AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-9714224-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| US-9714224-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| WO-2017062988-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-04-13 | — | — | WO | disclosed |
| EP-3081557-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Novartis AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-3081557-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Novartis AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-3081557-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Novartis AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| WO-2016142867-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016113668-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| CN-105777636-A | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | 诺华股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-05-26 | — | — | US | disclosed |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-05-26 | — | — | US | disclosed |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| EP-2595960-B1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2016-02-24 | — | — | EP | disclosed |
| EP-2595960-B1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2016-02-24 | — | — | EP | disclosed |
| US-9227968-B2 | Method of treatment or prophylaxis of inflammatory pain | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| EP-2525795-B1 | METHODS AND COMPOSITIONS FOR IMPROVED NERVE CONDUCTION VELOCITY | SPINIFEX PHARM PTY LTD (AU) | 2015-10-21 | — | — | EP | disclosed |
| EP-2525795-B1 | METHODS AND COMPOSITIONS FOR IMPROVED NERVE CONDUCTION VELOCITY | SPINIFEX PHARM PTY LTD (AU) | 2015-10-21 | — | — | EP | disclosed |
| US-9162985-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-10-20 | — | — | US | disclosed |
| US-9162985-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-10-20 | — | — | US | disclosed |
| US-9162985-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-10-20 | — | — | US | disclosed |
| US-9095587-B2 | Methods and compositions for improved nerve conduction velocity | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-04 | — | — | US | disclosed |
| US-9095587-B2 | Methods and compositions for improved nerve conduction velocity | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-04 | — | — | US | disclosed |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-16 | — | — | US | disclosed |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-16 | — | — | US | disclosed |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-16 | — | — | US | disclosed |
| US-8927575-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-06 | — | — | US | disclosed |
| US-8927575-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-06 | — | — | US | disclosed |
| US-8927575-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-06 | — | — | US | disclosed |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-22 | — | — | US | disclosed |
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-03-20 | — | — | US | disclosed |
| US-8614227-B2 | Salt and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-12-24 | — | — | US | disclosed |
| US-8614227-B2 | Salt and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-12-24 | — | — | US | disclosed |
| US-8551950-B2 | Method of treatment or prophylaxis of inflammatory pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-10-08 | — | — | US | disclosed |
| EP-2595960-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Spinifex Pharmaceuticals Pty Ltd (AU) | 2013-05-29 | — | — | EP | disclosed |
| EP-2595960-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Spinifex Pharmaceuticals Pty Ltd (AU) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131103-A1 | Methods and Compositions For Improved Nerve Conduction Velocity | NOVARTIS AG (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20130131103-A1 | Methods and Compositions For Improved Nerve Conduction Velocity | NOVARTIS AG (CH) | 2013-05-23 | — | — | US | disclosed |
| CN-103003244-A | Salts and solvates of tetrahydroisoquinoline derivatives | SPINIFEX PHARM PTY LTD | 2013-03-27 | — | — | CN | disclosed |
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD, (AU) | 2012-01-26 | — | — | US | disclosed |
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD, (AU) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010843-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010843-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010843-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2012-01-26 | — | — | WO | disclosed |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | UNIVERSITY OF QUEENSLAND (AU) | 2010-11-18 | — | — | US | disclosed |
| EP-1996183-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106938-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-09-27 | — | — | WO | disclosed |
| US-5525614-A | TREATING VASCULAR RESTENOSIS, CNS DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384097-B2 | Tetrahydroisoquinoline derivative, preparation method therefor and use thereof | AGTR2, AGTR1, AVPR2 | AGTR2 1/4885AGTR1 2/4885 |
| US-10308628-B2 | Heterocyclic compounds and methods for their use | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20190070153-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASES | ACE, AGT, AGTR2 | AGTR2 3/4885AGTR1 6/4885 |
| US-20130131103-A1 | Methods and Compositions For Improved Nerve Conduction Velocity | GAP43, CHRNB3, CHRNB4 | AGTR2 6/4885AGTR1 7/4885 |
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | AGTR2, AGTR1, HCAR2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20230242522-A1 | SALT OF TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | AGTR2, AGTR1, SLC5A11 | AGTR2 1/4885AGTR1 2/4885 |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | AGTR2, AGTR1, HCAR2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AGTR2 126/4885AGTR1 181/4885 |
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | REN, SUDS3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AGTR2 75/4885AGTR1 97/4885 |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | AGTR2, AGTR1, AVPR2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20180057477-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AGTR2 126/4885AGTR1 181/4885 |
| US-20190152918-A1 | CRYSTALLINE CALCIUM SALT OF (S)-2-(DIPHENYLACETYL)-1,2,3,4-TETRAHYDRO-6-METHOXY-5-(PHENYLMETHOXY)-3-ISOQUINOLINE CARBOXYLIC ACID | CACNA1S, CA2, CACNA1A | AGTR2 88/4885AGTR1 95/4885 |
| US-20210206724-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | AGTR2, AGTR1, AVPR2 | AGTR2 1/4885AGTR1 2/4885 |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | AGTR2, AGTR1, ACE2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, AGT | AGTR2 1/4885AGTR1 2/4885 |
| US-10987343-B2 | Compositions and methods for treating pulmonary diseases | ACE, AGT, AGTR2 | AGTR2 3/4885AGTR1 6/4885 |
| US-20200206196-A1 | Antiviral Drugs | ACE2, MAVS, EIF2AK2 | AGTR2 13/4885AGTR1 19/4885 |
| US-20210277021-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | AGTR2, AGTR1, AVPR2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.